KemPharm (KMPH) Announces Positive Results from KP511 Phase 1; Comparable Oral PK to Hydromorphone Demonstrated
Tweet Send to a Friend
KemPharm, Inc. (Nasdaq: KMPH) announced results from a Phase 1 proof-of-concept trial (KP511.101) with KP511, KemPharm’s prodrug of hydromorphone ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
